Cyclosporine/ketoconazole reduces treatment costs for nephrotic syndrome

Indian Journal of Nephrology

Volumn 23, Issue 6, 2013, Pages 419-423

  Iyengar, A ^a   Kamath, N ^a   Phadke, K D ^a   Bitzan, M ^b  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Azoles; Co administration; Cyclosporine; India; Nephrotic syndrome; Pediatric

Indexed keywords

ALBUMIN; CREATININE; CYCLOSPORIN A; KETOCONAZOLE; LIVER ENZYME;

ADOLESCENT; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERVENTION STUDY; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; NEPHROTIC SYNDROME; PATIENT COMPLIANCE; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; PRURITUS; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SYSTEMIC THERAPY; VOMITING;

EID: 84887511101     PISSN: 09714065     EISSN: 19983662     Source Type: Journal    
DOI: 10.4103/0971-4065.120338     Document Type: Article

References (29)

1. Bagga A, Mantan M. Nephrotic syndrome in children. Indian J Med Res 2005;122:13-28.
2. van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011;26:881-92.
3. Torban E, Bitzan M, Goodyer P. Recurrent focal segmental glomerulosclerosis: A discrete clinical entity. Int J Nephrol 2012;2012:246128.
4. Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: A randomized controlled trial. Am J Kidney Dis 2009;53:760-9.
5. Tejani AT, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, Khawar MR. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int 1988;33:729-34.
6. Gerntholtz T, Pascoe MD, Botha JF, Halkett J, Kahn D. The use of a cyclosporin-ketoconazole combination: Making renal transplantation affordable in developing countries. Eur J Clin Pharmacol 2004;60:143-8.
7. Daneshmend TK. Ketoconazole-cyclosporin interaction. Lancet 1982;2:1342-3.
8. Berkovitch M, Bitzan M, Matsui D, Finkelstein H, Balfe JW, Koren G. Pediatric clinical use of the ketoconazole/cyclosporin interaction. Pediatr Nephrol 1994;8:492-3.
9. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34.
10. Sobh M, el-Agroudy A, Moustafa F, Harras F, el-Bedewy M, Ghoneim M. Coadministration of ketoconazole to cyclosporin-treated kidney transplant recipients: A prospective randomized study. Am J Nephrol 1995;15:493-9.
11. Sobh MA, Hamdy AF, El Agroudy AE, El Sayed K, El-Diasty T, Bakr MA, et al. Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: Long-term follow-up and study of metabolic consequences. Am J Kidney Dis 2001;37:510-7.
12. Martin JE, Daoud AJ, Schroeder TJ, First MR. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999;15:317-37.
13. Gonzalez F, Espinoza M, Herrera P, Rocca X, Reynolds E, Lorca E, et al. Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial. Transplant Proc 2010;42:270-2.
14. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 2004;68:1889-902.
15. Alexander JW, First MR, Hariharan S, Penn I, Schroeder T, Ryckman F, et al. Recent contributions to transplantation at the University of Cincinnati. Clin Transpl 1991:159-78.
16. Albengres E, Tillement JP. Cyclosporin and ketoconazole, drug interaction or therapeutic association? Int J Clin Pharmacol Ther Toxicol 1992;30:555-70.
17. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995;7;333:628-33.
18. Jones TE. The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations. Clin Pharmacokinet 1997;32:357-67.
19. Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther 1999;66:66-75.
20. Sabry A, El-Husseini A, El-Dahshan K, Sobh M. Single-center experience with cyclosporine for treatment of idiopathic minimal change nephrotic syndrome in children. Iran J Kidney Dis 2009;3:127-35.
21. El-Husseini A, El-Basuony F, Donia A, Mahmoud I, Hassan N, Sayed-Ahmad N, et al. Concomitant administration of cyclosporine and ketoconazole in idiopathic nephrotic syndrome. Nephrol Dial Transplant 2004;19:2266-71.
22. el-Husseini A, el-Basuony F, Mahmoud I, Donia A, Hassan N, Sayed-Ahmad N, et al. Co-administration of cyclosporine and ketoconazole in idiopathic childhood nephrosis. Pediatr Nephrol 2004;19:976-81.
23. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney Int 2007;72:1429-47.
24. Beresini MH, Davalian D, Alexander S, Toton-Quinn R, Barnett B, Cerelli MJ, et al. Evaluation of EMIT Cyclosporine Assay for use with whole blood. Clin Chem 1993;39:2235-41.
25. Soldin SJ, Steele BW, Witte DL, Wang E, Elin RJ, College of American Pathologists Study. Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study. Arch Pathol Lab Med 2003;127:19-22.
26. Aviles-Gomez R, Luquin-Arellano VH, Garcia-Garcia G, Ibarra-Hernandez M, Briseno-Renteria G Is renal replacement therapy for all possible in developing countries?. Ethn Dis 2006;16:S270-2.
27. Machado M, O'Brodovich R, Krahn M, Einarson TR. International drug price comparisons: Quality assessment. Rev Panam Salud Publica 2011;29:46-51.
28. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72.
29. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730-44.